| Literature DB >> 28331100 |
Patricia S Pardo1, Ameena Hajira2, Aladin M Boriek1, Junaith S Mohamed2,3.
Abstract
Increased activation of catabolic pathways, including apoptosis causes sarcopenia. However, the precise molecular mechanism that initiates apoptosis during aging is not well understood. Here, we report that aging alters miRNA expression profile in mouse skeletal muscle as evidenced by miRNA microarray and real-time PCR. We identified miR-434-3p as a highly downregulated miRNA in the skeletal muscle of aging mice. Myocytes transfected with miR-434-3p mimic prevents apoptosis induced by various apoptotic stimuli, and co-transfection of miR-434-3p antagomir abolishes the inhibitory role of miR-434-3p. We found that miR-434-3p inhibits apoptosis by targeting the eukaryotic translation initiation factor 5A1 (eIF5A1). Overexpression of miR-434-3p in myocytes reduces the loss of mitochondrial transmembrane potential, and activation of caspases-3, -8 and -9 by suppressing eIF5A1 in response to various apoptotic stimuli whereas inhibition of miR-434-3p reversed this scenario. Skeletal muscles from aging mice exhibit low levels of miR-434-3p and high levels of eIF5A1, suggesting a possible role for miR-434-3p in the initiation of apoptosis in aging muscle. Overall, our data identified for the first time that miR-434-3p is an anti-apoptotic miRNA that may be therapeutically useful for treating muscle atrophy in various pathophysiological conditions, including sarcopenia.Entities:
Keywords: aging; mitochondria; sarcopenia; skeletal muscle
Mesh:
Substances:
Year: 2017 PMID: 28331100 PMCID: PMC5391215 DOI: 10.18632/aging.101207
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Differentially regulated miRNAs in the GA muscle of aging mouse
| No | miRNA | Young | Old | Log2 | No | miRNAs | Young | Old | Log2 |
|---|---|---|---|---|---|---|---|---|---|
| 1 | miR-146b | 410 | 1134 | 1.88 | 35 | −0.2 | |||
| 2 | miR-146 | 2997 | 8074 | 1.61 | 36 | −0.2 | |||
| 3 | miR-155 | 448 | 1338 | 1.28 | 37 | −0.21 | |||
| 4 | miR-29b | 345 | 626 | 1.16 | 38 | −0.23 | |||
| 5 | miR-223 | 531 | 1646 | 0.99 | 39 | 8127 | −0.23 | ||
| 6 | miR-671 | 384 | 565 | 0.74 | 40 | −0.23 | |||
| 7 | miR-705 | 4676 | 8084 | 0.71 | 41 | −0.25 | |||
| 8 | 0.49 | 42 | −0.25 | ||||||
| 9 | miR-203 | 350 | 661 | 0.48 | 43 | 7839 | −0.27 | ||
| 10 | miR-221 | 962 | 862 | 0.35 | 44 | −0.28 | |||
| 11 | 0.29 | 45 | −0.28 | ||||||
| 12 | miR-92 | 1753 | 3888 | 0.28 | 46 | −0.31 | |||
| 13 | miR-29c | 2183 | 3688 | 0.26 | 47 | miR-133a* | 1493 | 956 | −0.31 |
| 14 | miR-98 | 3911 | 6513 | 0.19 | 48 | −0.31 | |||
| 15 | miR-224 | 284 | 500 | 0.11 | 49 | −0.32 | |||
| 16 | miR-805 | 3315 | 6839 | 0.1 | 50 | miR-451 | 6331 | 3093 | −0.34 |
| 17 | miR-222 | 711 | 546 | 0.08 | 51 | miR-139 | 1117 | 934 | −0.34 |
| 18 | miR-15b | 2903 | 4074 | 0.05 | 52 | miR-185 | 3866 | 4299 | −0.35 |
| 19 | 0.03 | 53 | miR-10b | 4182 | 3948 | −0.35 | |||
| 20 | 0.02 | 54 | miR-191 | 6182 | 7454 | −0.36 | |||
| 21 | miR-126-5p | 2498 | 2630 | 0.01 | 55 | 9958 | −0.4 | ||
| 22 | −0.06 | 56 | 6830 | −0.4 | |||||
| 23 | −0.07 | 57 | miR-214 | 8430 | 5777 | −0.41 | |||
| 24 | miR-361 | 1776 | 2579 | −0.08 | 58 | miR-103 | 3167 | 2176 | −0.49 |
| 25 | −0.08 | 59 | −0.5 | ||||||
| 26 | −0.09 | 60 | −0.52 | ||||||
| 27 | −0.1 | 61 | −0.53 | ||||||
| 28 | −0.1 | 62 | −0.53 | ||||||
| 29 | miR-10a | 5599 | 5923 | −0.11 | 63 | miR-22 | 7043 | 6474 | −0.56 |
| 30 | −0.11 | 64 | 8288 | −0.62 | |||||
| 31 | −0.12 | 65 | miR-107 | 3321 | 2128 | −0.65 | |||
| 32 | miR-132 | 500 | 554 | −0.15 | 66 | 7357 | −0.66 | ||
| 33 | miR-30a-3p | 1703 | 2266 | −0.17 | 67 | miR-20a | 1461 | 806 | −0.67 |
| 34 | −0.19 | 68 | miR-15a | 2152 | 1662 | −0.69 | |||
| 34 | miR-17-5p | 520 | 420 | −0.7 | 94 | miR-181a | 3521 | 1470 | −1.14 |
| 36 | miR-674 | 633 | 416 | −0.7 | 95 | miR-199a | 994 | 405 | −1.2 |
| 37 | miR-320 | 5549 | 3168 | −0.72 | 96 | miR-62101a | 1142 | 524 | −1.22 |
| 38 | miR-676 | 701 | 326 | −0.73 | 97 | miR-72630 | 1528 | 877 | −1.25 |
| 39 | −0.76 | 98 | miR-36564 | 500 | 400 | −1.29 | |||
| 40 | miR-151 | 973 | 634 | −0.76 | 99 | miR-30e65 | 1651 | 836 | −1.29 |
| 41 | miR-762 | 6082 | 3620 | −0.78 | 100 | miR-690 | 2803 | 1669 | −1.3 |
| 42 | miR-181b | 1882 | 1210 | −0.78 | 101 | miR-322 | 773 | 291 | −1.34 |
| 43 | miR-143 | 9802 | 5554 | −0.79 | 102 | miR-424 | 3305 | 1568 | −1.38 |
| 44 | miR-25 | 4761 | 2932 | −0.8 | 103 | miR-128b | 1989 | 1114 | −1.44 |
| 45 | miR-342 | 1915 | 970 | −0.82 | 104 | miR-128a | 2230 | 885 | −1.48 |
| 46 | miR-378 | 988 | 459 | −0.85 | 105 | 5739 | −1.49 | ||
| 47 | miR-152 | 4130 | 2123 | −0.86 | 106 | miR-194 | 510 | 184 | −1.5 |
| 48 | miR-130a | 627 | 497 | −0.87 | 107 | miR-101b | 995 | 366 | −1.5 |
| 49 | miR-140* | 1250 | 683 | −0.89 | 108 | miR-148a | 975 | 367 | −1.56 |
| 50 | miR-28 | 1060 | 493 | −0.92 | 109 | miR-199b | 800 | 213 | −1.59 |
| 51 | miR-106b | 598 | 293 | −0.95 | 110 | miR-335 | 720 | 210 | −2.32 |
| 52 | miR-99b | 3513 | 1699 | −0.98 | 111 | miR-127 | 1989 | 282 | −2.33 |
| 53 | let-7d* | 527 | 267 | −1 | 112 | miR-379 | 2765 | 500 | −2.48 |
| 54 | miR-328 | 652 | 300 | −1 | 113 | miR-541 | 557 | 137 | −2.55 |
| 55 | miR-99a | 5591 | 2684 | −1.01 | 114 | miR-382 | 729 | 116 | −3.12 |
| 56 | miR-100 | 5263 | 2899 | −1.03 | 115 | miR-329 | 1551 | 93 | −3.57 |
| 57 | miR-499 | 1377 | 901 | −1.04 | 116 | miR-299 | 1767 | 92 | −3.97 |
| 58 | miR-181d | 559 | 269 | −1.05 | 117 | miR-434-3p | 1767 | 154 | −4.08 |
| 59 | miR-149 | 3221 | 1683 | −1.06 |
Underlines indicate differentially regulated miRNAs at signal intensities >10,000.
Figure 1Aging alters miRNA expression profile in skeletal muscle
(A and B) Total RNA was isolated from the skeletal muscles from three-month-old young control and 26-month-old aging mice and used in miRNA microarray analyses to determine the expression levels of mouse miRNAs. Data on the scatter plot shows log10-transformed signal intensities for each probe labeled with Cy3 (young) and Cy5 (aging) mice (A). The heat map shows miRNAs significantly differentially expressed in skeletal muscle from aging mice (B). Each dot represents one miRNA probe. (C) Differentially-regulated (≥ 1.5 fold) age-related miRNAs.
Figure 2Validation of aging associated miRNA expression profile
(A and B) A portion of RNA used in the microarray was used in qPCR (A) and in a separate experiment by solution hybridization technique with 5' biotin-labeled miRNAs (B) to confirm the expression level of miRNAs that were differentially regulated ≥1.5-fold in the microarray. U6 served as both loading control and normalizer. Gel pictures are representative of three independent experiments. Each bar indicates mean ± SEM (n = 3). White and black bars indicate the levels of miRNA measured by microarray and qPCR, respectively.
Predicted biological pathways linked to differentially regulated miRNAs (>1.5-fold) in the GA muscle of aging mouse
| No | KEGG pathway | p-value | Genes | miRNAs |
|---|---|---|---|---|
| 1 | ||||
| 2 | Pathways in cancer | 1.79E-10 | 88 | 13 |
| 3 | ||||
| 4 | HTLV-I infection | 6.23E-12 | 77 | 14 |
| 5 | ||||
| 6 | ||||
| 7 | ||||
| 8 | Transcriptional misregulation in cancer | 2.36E-11 | 58 | 14 |
| 9 | Protein processing in endoplasmic reticulum | 3.17E-12 | 53 | 12 |
| 10 | Axon guidance | 5.07E-23 | 52 | 13 |
| 11 | Endocytosis | 5.35E-05 | 51 | 13 |
| 12 | Dopaminergic synapse | 2.95E-15 | 48 | 10 |
| 13 | ||||
| 14 | Chemokine signaling pathway | 0.000375 | 45 | 14 |
| 15 | ||||
| 16 | Calcium signaling pathway | 0.000783 | 43 | 12 |
| 17 | Hepatitis B | 1.72E-06 | 41 | 14 |
| 18 | Neurotrophin signaling pathway | 9.78E-12 | 40 | 13 |
| 19 | Tuberculosis | 0.003419 | 40 | 13 |
| 20 | Glutamatergic synapse | 3.53E-11 | 39 | 11 |
| 21 | T cell receptor signaling pathway | 1.38E-11 | 37 | 14 |
| 22 | Cholinergic synapse | 7.49E-07 | 36 | 11 |
| 23 | RNA transport | 0.021696 | 35 | 13 |
| 24 | Retrograde endocannabinoid signaling | 1.20E-07 | 34 | 9 |
| 25 | ErbB signaling pathway | 1.43E-14 | 33 | 12 |
| 26 | Oocyte meiosis | 9.73E-05 | 32 | 11 |
| 27 | ||||
| 28 | Prostate cancer | 8.27E-12 | 31 | 13 |
| 29 | Osteoclast differentiation | 7.19E-05 | 31 | 11 |
| 30 | Serotonergic synapse | 0.005448 | 30 | 11 |
| 31 | Chagas disease (American trypanosomiasis) | 2.70E-05 | 29 | 13 |
| 32 | Hepatitis C | 0.027024 | 29 | 13 |
| 33 | Spliceosome | 0.027549 | 29 | 11 |
| 34 | Chronic myeloid leukemia | 4.29E-10 | 27 | 13 |
| 35 | Hypertrophic cardiomyopathy (HCM) | 1.32E-08 | 27 | 8 |
| 36 | Renal cell carcinoma | 8.82E-08 | 27 | 12 |
| 37 | GnRH signaling pathway | 5.84E-07 | 27 | 13 |
| 38 | Melanogenesis | 7.49E-05 | 27 | 11 |
| 39 | GABAergic synapse | 0.004621 | 27 | 9 |
| 40 | Long-term potentiation | 8.27E-12 | 26 | 11 |
| 41 | Small cell lung cancer | 6.84E-07 | 26 | 13 |
| 42 | Dilated cardiomyopathy | 3.62E-06 | 26 | 8 |
| 43 | ||||
| 44 | mRNA surveillance pathway | 0.001512 | 26 | 12 |
| 45 | Pancreatic cancer | 2.37E-08 | 25 | 11 |
| 46 | Melanoma | 2.80E-08 | 25 | 11 |
| 47 | B cell receptor signaling pathway | 1.52E-07 | 25 | 13 |
| 48 | ||||
| 49 | ||||
| 50 | ||||
| 51 | Arrhythmogenic right ventricular cardiomyopathy | 0.000115 | 23 | 10 |
| 52 | Progesterone-mediated oocyte maturation | 0.000564 | 23 | 11 |
| 53 | Amphetamine addiction | 0.00381 | 23 | 12 |
| 54 | ||||
| 55 | ||||
| 56 | Glioma | 6.54E-05 | 22 | 12 |
| 57 | Bacterial invasion of epithelial cells | 7.19E-05 | 21 | 8 |
| 58 | Salmonella infection | 0.000308 | 21 | 9 |
| 59 | ||||
| 60 | ||||
| 61 | Gastric acid secretion | 0.001232 | 20 | 9 |
| 62 | Non-small cell lung cancer | 2.32E-06 | 19 | 11 |
| 63 | Colorectal cancer | 0.000274 | 19 | 11 |
| 64 | ||||
| 65 | Endometrial cancer | 1.79E-06 | 18 | 10 |
| 66 | ||||
| 67 | Acute myeloid leukemia | 3.07E-05 | 17 | 13 |
| 68 | Amyotrophic lateral sclerosis (ALS) | 9.65E-05 | 17 | 11 |
| 69 | ||||
| 70 | RIG-I-like receptor signaling pathway | 0.01547 | 17 | 13 |
| 71 | Fc epsilon RI signaling pathway | 0.022008 | 17 | 10 |
| 72 | ||||
| 73 | ||||
| 74 | ||||
| 75 | Circadian rhythm | 5.32E-08 | 14 | 7 |
| 76 | Bladder cancer | 0.001543 | 13 | 9 |
| 77 | Basal transcription factors | 0.002387 | 13 | 11 |
| 78 | ||||
| 79 | Aldosterone-regulated sodium reabsorption | 0.001227 | 12 | 11 |
| 80 | Vasopressin-regulated water reabsorption | 0.045885 | 12 | 6 |
| 81 | Dorso-ventral axis formation | 1.52E-07 | 10 | 10 |
| 82 | ||||
| 83 | Prion diseases | 3.96E-10 | 7 | 7 |
| 84 | Proximal tubule bicarbonate reclamation | 0.004531 | 7 | 5 |
| 85 | Taurine and hypotaurine metabolism | 0.004447 | 4 | 3 |
| 86 | D-Glutamine and D-glutamate metabolism | 0.000519 | 3 | 3 |
| 87 |
Bold indicates skeletal muscle specific pathways.
Predicted biological pathways controlled by up-regulated miRNAs
| No | KEGG pathway | p-value | Genes | miRNAs |
|---|---|---|---|---|
| 1 | MAPK signaling pathway | 0.028946 | 6 | 2 |
| 2 | NF-kappa B signaling pathway | 3.96E-05 | 4 | 2 |
| 3 | Apoptosis | 0.010616 | 4 | 2 |
| 4 | Toll-like receptor signaling pathway | 0.001913 | 3 | 2 |
| 5 | VEGF signaling pathway | 0.01676 | 3 | 2 |
| 6 | ECM-receptor interaction | 0.004068 | 2 | 2 |
| 7 | TGF-beta signaling pathway | 0.029883 | 2 | 2 |
Predicted biological pathways controlled by downregulated miRNAs
| No | KEGG pathway | p-value | Genes | miRNAs |
|---|---|---|---|---|
| 1 | PI3K-Akt signaling pathway | 7.21E-12 | 90 | 13 |
| 2 | MAPK signaling pathway | 1.90E-20 | 82 | 14 |
| 3 | Regulation of actin cytoskeleton | 8.73E-13 | 65 | 14 |
| 4 | Focal adhesion | 8.92E-16 | 63 | 12 |
| 5 | Wnt signaling pathway | 3.09E-23 | 59 | 13 |
| 6 | Ubiquitin mediated proteolysis | 1.08E-10 | 45 | 12 |
| 7 | Insulin signaling pathway | 3.53E-11 | 43 | 13 |
| 8 | Cell cycle | 0.004448 | 32 | 13 |
| 9 | Apoptosis | 3.24E-05 | 26 | 12 |
| 10 | TGF-beta signaling pathway | 4.55E-05 | 25 | 12 |
| 11 | Adherens junction | 3.18E-05 | 23 | 11 |
| 12 | p53 signaling pathway | 3.29E-07 | 23 | 10 |
| 13 | mTOR signaling pathway | 1.20E-07 | 22 | 11 |
| 14 | VEGF signaling pathway | 1.20E-07 | 22 | 11 |
| 15 | Phosphatidylinositol signaling system | 0.005448 | 21 | 10 |
| 16 | Adipocytokine signaling pathway | 4.03E-05 | 20 | 11 |
| 17 | Gap junction | 0.00222 | 19 | 12 |
| 18 | Inositol phosphate metabolism | 0.000552 | 17 | 10 |
| 19 | Lysine degradation | 3.31E-07 | 17 | 9 |
| 20 | Calcium reabsorption | 0.005096 | 16 | 9 |
| 21 | Hedgehog signaling pathway | 2.88E-05 | 16 | 8 |
| 22 | Type II diabetes mellitus | 0.00052 | 15 | 8 |
| 23 | Sphingolipid metabolism | 0.028141 | 13 | 7 |
| 24 | Alanine, aspartate and glutamate metabolism | 0.016589 | 10 | 7 |
| 25 | Biotin metabolism | 0.00381 | 1 | 1 |
Predicted biological pathways controlled by miR-434-3p
| No | KEGG pathway | p-value | Genes | miRNAs |
|---|---|---|---|---|
| 1 | Fatty acid degradation | 2.65E-10 | 1 | 1 |
| 2 | Fatty acid metabolism | 2.58E-06 | 1 | 1 |
| 3 | Sphingolipid metabolism | 0.002379 | 3 | 1 |
| 4 | MAPK signaling pathway | 0.002885 | 10 | 1 |
| 5 | N-Glycan biosynthesis | 0.003339 | 3 | 1 |
| 6 | Valine, leucine and isoleucine degradation | 0.005375 | 1 | 1 |
| 7 | Apoptosis | 0.010371 | 3 | 1 |
| 8 | PI3K-Akt signaling pathway | 0.021814 | 7 | 1 |
Figure 3eIF5A1 is a target mRNA of miR-434-3p
(A) Sequence alignment of putative miR-434-3p targeting site in the 3′-UTR of eIF5A1 shows high levels of complementarity. (B-D) Myotubes were transfected with miR-434-3p mimetic or NS-mimetic. miR-434-3p overexpression was determined by qPCR assay (B). U6 served as a normalizer. eIF5A1 mRNA levels were analyzed 24 h after transfection by qPCR (C) and eIF5A1 protein levels were analyzed 36 h after transfection by Western blot (D). (E) Sequence information represents the site directed mutagenesis on the 3′UTR of eIF5A1. Red letters indicate mutated nucleotide and arrows indicate nucleotide position. (F) The eIF5A1 3′-UTR–luciferase construct or eIF5A1 3′-UTR mutated–luciferase construct were co-transfected with NS-mimetic, miR-434-3p mimetic, miR-434-3p antagomir or SC-miR. Forty-eight hours after transfection, cells were collected, and then firefly luciferase activities were estimated and normalized to Renilla luciferase activities. Each bar indicates mean ± SEM (n = 3). *P < 0.05 vs. NS-miR. Gel pictures are representative of three independent experiments.
Figure 4miR-434-3p protects apoptosis through eIF5A1
Myotubes were transfected with NS-mimetic, miR-434-3p mimetic with or without miR-434-3p antagomir or no transfection for 24 h followed by eight hours TPEN (100 μM) or Stps (1 μM) incubation. (A and B) Apoptosis (%) was measured by MTT assay in TPEN treated and non-treated myotubes (A) and the expression of eIF5A1 protein levels were determined by western blot (B). (C and D) Apoptosis (%) was measured by MTT assay in Stps treated and non-treated myotubes (C) and the expression of eIF5A1 protein levels were determined by western blot (D). (E) Myotubes were transfected with non-specific siRNA (NS-siRNA) or eIF5A1 siRNA for 24 h followed by eight hours TPEN (100 μM) or Stps (1 μM) incubation. Apoptosis (%) was measured by MTT assay. (F) miR-434-3p and eIF5A1 levels in young and aging GA muscles were determined by solution hybridization and western blot methods, respectively. U6 and GAPDH were served as loading controls for miR-434-3p and eIF5A1, respectively. Gel pictures are representative of three independent experiments. Each bar indicates mean ± SEM (n = 3). *, p< 0.05 vs. control; ϕ, p <0.05 vs. NS-miR or NS-siRNA; δ, p < 0.05 vs. mimic.
Figure 5miR-434-3p protects myotubes from caspase activation and loss of mitochondrial membrane potential
Myotubes were transfected with NS-mimetic, miR-434-3p mimetic, miR-434-3p antagomir or no transfection for 24 h followed by eight hours TPEN (100 μM) or Stps (1 μM) incubation. (A and B) Enzymatic activities of caspase-3, −8 and −9 in myotubes treated with TPEN (A) and Stsp (B) were determined by caspase specific fluorogenic substrates. (C) Untreated (control) or treated myotubes were stained with JC-1 and observed under TRITC (590 nm) and GFP (530 nm) filters. %Δψm index represents the ratio of red to green fluorescence. Each bar indicates mean ± SEM (n = 3). *, p < 0.05 vs. control; ϕ, p < 0.05 vs. NS-miR; δ, p < 0.05 vs. mimic.